{"title":"高收入国家镰状细胞病孕妇的循证管理。","authors":"Eugene Oteng-Ntim, Panicos Shangaris","doi":"10.1182/hematology.2022000378","DOIUrl":null,"url":null,"abstract":"<p><p>Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).</p>","PeriodicalId":12973,"journal":{"name":"Hematology. American Society of Hematology. Education Program","volume":"2022 1","pages":"408-413"},"PeriodicalIF":2.9000,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820817/pdf/hem.2022000378.pdf","citationCount":"0","resultStr":"{\"title\":\"Evidence-based management of pregnant women with sickle cell disease in high-income countries.\",\"authors\":\"Eugene Oteng-Ntim, Panicos Shangaris\",\"doi\":\"10.1182/hematology.2022000378\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).</p>\",\"PeriodicalId\":12973,\"journal\":{\"name\":\"Hematology. American Society of Hematology. Education Program\",\"volume\":\"2022 1\",\"pages\":\"408-413\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2022-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820817/pdf/hem.2022000378.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology. American Society of Hematology. Education Program\",\"FirstCategoryId\":\"95\",\"ListUrlMain\":\"https://doi.org/10.1182/hematology.2022000378\",\"RegionNum\":3,\"RegionCategory\":\"教育学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"EDUCATION, SCIENTIFIC DISCIPLINES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology. American Society of Hematology. Education Program","FirstCategoryId":"95","ListUrlMain":"https://doi.org/10.1182/hematology.2022000378","RegionNum":3,"RegionCategory":"教育学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
Evidence-based management of pregnant women with sickle cell disease in high-income countries.
Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).